UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Sana Biotechnology, Inc. (NASDAQ:SANA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 2.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 253,899 shares of the company’s stock after buying an additional 6,823 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.11% of Sana Biotechnology worth $1,056,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of SANA. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Sana Biotechnology by 17.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company’s stock worth $146,000 after acquiring an additional 5,338 shares during the period. FMR LLC increased its position in shares of Sana Biotechnology by 16.3% during the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock valued at $131,494,000 after purchasing an additional 4,438,949 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Sana Biotechnology by 11.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company’s stock worth $4,359,000 after purchasing an additional 105,382 shares during the period. Intech Investment Management LLC purchased a new position in shares of Sana Biotechnology in the 3rd quarter worth about $240,000. Finally, Cornercap Investment Counsel Inc. bought a new position in Sana Biotechnology during the third quarter valued at about $67,000. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Stock Performance

Shares of Sana Biotechnology stock opened at $1.69 on Thursday. The stock has a market capitalization of $376.21 million, a P/E ratio of -1.20 and a beta of 1.33. Sana Biotechnology, Inc. has a 52-week low of $1.65 and a 52-week high of $12.00. The stock’s 50-day simple moving average is $3.02 and its 200 day simple moving average is $4.57.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. Equities research analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the sale, the director now directly owns 2,848,121 shares in the company, valued at $11,620,333.68. This represents a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 31.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Sana Biotechnology in a research report on Wednesday, November 27th. JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.